Format

Send to

Choose Destination
Am J Clin Dermatol. 2018 Apr;19(2):275-286. doi: 10.1007/s40257-018-0352-y.

Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison.

Author information

1
Department of Dermato-Cancerology, CIC 1413, CRCINA Inserm 1232, CHU Nantes, Nantes, France. brigitte.dreno@atlanmed.fr.
2
Innovaderm Research, Montreal, Canada.
3
Dre Angélique Gagné-Henley MD Inc, St-Jérôme, Québec, Canada.
4
Toronto Research Centre Inc, Toronto, Ontario, Canada.
5
Lynde Institute for Dermatology, Markham, Ontario, Canada.
6
Galderma R&D, Sophia Antipolis, France.
7
University of Western Ontario, London, Ontario, Canada.
8
Windsor Clinical Research Inc, Windsor, Ontario, Canada.

Abstract

BACKGROUND:

Very few clinical trials have investigated the effect of topical acne treatment on scarring.

OBJECTIVES:

Our objective was to evaluate the efficacy of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) in atrophic acne scar formation in patients with acne.

METHODS:

In this multicenter, randomized, investigator-blinded, vehicle-controlled study, subjects with moderate or severe facial acne (Investigator's Global Assessment [IGA] score 3 or 4; ≥ 25 inflammatory lesions; ten or more atrophic acne scars) applied A0.3/BPO2.5 or vehicle daily per half face for 24 weeks. Subjects with acne requiring systemic treatment were excluded. Assessments included investigator atrophic acne scar count, Scar Global Assessment (SGA), acne lesion count, IGA, skin roughness and skin texture, subject self-assessment of clinical acne-related scars and satisfaction questionnaire, tolerability, and safety.

RESULTS:

Included subjects (n = 67) had mainly moderate acne (92.5% IGA 3); mean scores at baseline were approximately 40 acne lesions and 12 scars per half face. By week 24, the change from baseline in total scar count was - 15.5% for A0.3/BPO2.5 versus  + 14.4% for vehicle (approximately 30% difference), with a mean of 9.5 scars versus 13.3 per half face, respectively (p < 0.0001). For SGA at week 24, a total of 32.9% with A0.3/BPO2.5 versus 16.4% with vehicle (p < 0.01) were clear/almost clear. Inflammatory acne lesions decreased by 86.7% for A0.3/BPO2.5 versus 57.9% for vehicle (p < 0.0001), and 64.2 versus 19.4% of subjects, respectively, were IGA clear/almost clear (p < 0.0001) at week 24. Treatment-related AEs were reported by 20.9% for A0.3/BPO2.5 versus 9% for vehicle side, most commonly skin irritation (14.9 vs. 6%, respectively).

CONCLUSIONS:

Topical A0.3/BPO2.5 prevented and reduced atrophic scar formation. Scar count increased with vehicle (+ 14.4%) but decreased with A0.3/BPO2.5 (- 15.5%) over 24 weeks.

TRIAL REGISTRY:

ClinicalTrials.gov identifier NCT02735421.

PMID:
29549588
PMCID:
PMC5978908
DOI:
10.1007/s40257-018-0352-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center